ΒιΆΉ΄«Γ½

Meeting Coverage

ASCO GI

American Society of Clinical Oncology
The Gastrointestinal Cancers Symposium

ASCO GI: Targeted Agent Slows Neuroendocrine Tumors

ORLANDO -- Patients with progressive pancreatic neuroendocrine tumors lived twice as long without progression when treated with sunitinib (Sutent) compared with placebo, data from a French clinical trial showed.

image

Latest ASCO GI Meeting Coverage

ASCO GI: Avastin Gives No Survival Advantage in Advanced Pancreatic Cancer

ORLANDO -- The addition of Avastin (bevacizumab) to Gemzar (gemcitabine) did not improve survival of advanced pancreatic cancer in a randomized trial, researchers here reported.

January 22, 2007

Latest Oncology/Hematology Meeting Coverage